IP Library › Assignment 014580/0798
Patent Assignment
Reel/Frame 014580/0798

Security Agreement

Recorded: 2004-04-30 Received: 2004-04-30 Pages: 14
Assignors
AAIPHARMA INC.
Executed: 2004-04-23
Assignee
SILVER POINT FINANCE LLC
600 STEAMBOAT ROAD, GREENWICH, CT, 06830, UNITED STATES
Covered Properties (28)
Flexible Spinal Stabilization System and Method
Application: 10/793,308 →
Polyether brevetoxin derivatives as a treatment for neurotoxic shellfish poisoning and ciguatera fish poisoning
Application: 60/504,670 →
Method of reducing the risk of adverse cardiovascular events
Application: 60/499,153 →
Granulated Pharmaceutical Formulations and Methods for Making the Same
Application: 10/439,865 →
Dry Blend Pharmaceutical Formulations
Application: 10/439,438 →
Alkoxy Substituted Benzimidazole Compounds, Pharmaceutical Preparations Containing the Same, and Methods of Using the Same
Application: 10/434,259 →
Dry-Blend Pharmaceutical Formulations
Application: 10/431,019 →
Form a of Fluoxetine Hydrochloride
Application: 10/136,582 →
Alkoxy Substituted Benzimidazole Compounds, Pharmaceutical Preparations Containing the Same, and Methods of Using the Same
Application: 10/189,659 →
Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4h-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof
Application: 10/109,513 →
Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof
Application: 10/109,086 →
Polymorphic form of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-alpha]pyrimidin-4-one and formulations thereof
Application: 10/108,729 →
Alkoxy Substituted Benzimidazole Compounds, Pharmaceutical Preparations Containing the Same, and Methods of Using the Same
Application: 10/057,659 →
Form a of Fluoxetine Hydrochloride
Application: 09/991,839 →
Polymorphic Forms of 6-[4-(1-Cyclohexyl-1H-Tetrazol-5-Yl)Butoxy]-3,4-Dihydro-2(1H)-Quinolinone
Application: 09/896,184 →
Polymorphic Forms of 6-[4-(1-Cyclohexyl-1H-Tetrazol-5-Yl)Butoxy]-3,4-Dihydro-2(1H)-Quinolinone
Application: 09/896,065 →
Polymorphic Forms of 6-[4-(1-Cyclohexyl-1H-Tetrazol-5-Yl)Butoxy]-3,4-Dihydro-2(1H)-Quinolinone
Application: 09/896,067 →
Polymorphic Forms of 6-[4-(1-Cyclohexyl-1H-Tetrazol-5-Yl)Butoxy]-3,4-Dihydro-2(1H)-Quinolinone
Application: 09/896,449 →
Polymorphic forms of 6-[4-(1-cyclohexyl-1H-tetrazol-5-YL)butoxy]-3,4-dihydro-2(1H)-quinolinone
Application: 09/896,185 →
Polymorphic Forms of 6-[4-(1-Cyclohexyl-1H-Tetrazol-5-Yl)Butoxy]-3,4-Dihydro-2(1H)-Quinolinone
Application: 09/896,800 →
Polymorphic Forms of 6-[4-(1-Cyclohexyl-1H-Tetrazol-5-Yl)Butoxy]-3,4-Dihydro-2(1H)-Quinolinone
Application: 09/896,448 →
Process for Purifying 6- Methoxy Omeprazole
Application: 09/839,449 →
Process for Purifying 6-Methoxy Omeprazole
Application: 09/839,395 →
Form a of fluoxetine hydrochloride
Application: 09/772,968 →
Form A of fluoxetine hydrochloride
Application: 09/773,015 →
Form a of fluoxetine hydrochloride
Application: 09/772,969 →
Form a of fluoxetine hydrochloride
Application: 09/773,016 →
Form a of fluoxetine hydrochloride
Application: 09/772,992 →